Clinical Manifestation, mNGS Based Diagnosis and Treatment of Pulmonary Mucormycosis with Rhizopus delemar in a Diabetic Patient
Xuesong Cheng,Tianyu Li,Fengsheng Wu,Dandan Liu
DOI: https://doi.org/10.2147/idr.s454029
2024-04-09
Infection and Drug Resistance
Abstract:Xuesong Cheng, 1 Tianyu Li, 2 Fengsheng Wu, 2 Dandan Liu 1 1 The Department of Pulmonary and Critical Care Medicine, Anhui No.2 Provincial People's Hospital, Hefei, People's Republic of China; 2 Genoxor Medical Science and Technology Inc., Shanghai, People's Republic of China Correspondence: Dandan Liu, Email Pulmonary mucormycosis is a severe and often fatal disease that commonly affects patients with underlying conditions, such as diabetes. Early diagnosis and appropriate treatment are crucial for improving survival rates. However, clinical diagnosis remains challenging due to difficulty in obtaining etiological evidence. In this particular case, the patient presented with a cough-producing bloody sputum, and a chest CT revealed lesions in the right upper lobe of the lung. The patient was ultimately diagnosed with pulmonary mucormycosis caused by Rhizopus delemar through clinical bronchoscopy biopsy and metagenomic next-generation sequencing (mNGS) analysis of bronchoalveolar lavage fluid sample. Subsequently, antifungal therapy using the less toxic Amphotericin B cholesterol Organosulfate complex was initiated, improving the patient's condition. In conclusion, our findings underscore the potential of mNGS to provide an accurate and rapid etiological diagnosis of pulmonary mucormycosis, offering a foundation for treatment. Keywords: Rhizopus delemar , pulmonary mucormycosis, metagenomic next generation sequencing, bronchoscopy biopsy Pulmonary mucormycosis is a rare invasive fungal infection caused by a pathogen of the order Mucorales, characterized by an acute onset, rapid progression, and high mortality. The incidence of pulmonary mucormycosis has been steadily increasing over the past few decades, posing a significant risk to human health. 1 Pulmonary mucormycosis primarily affects immunocompromised patients, such as those with malignant tumors, organ transplant recipients, and long-term users of immunosuppressants due to diabetes. 2,3 The genus Rhizopus of the Mucorales order is the primary pathogen responsible for pulmonary mucormycosis; among these, Rhizopus oryzae and Rhizopus microsporus are the most prevalent, with few reports on Rhizopus delemar as an important pathogen. 4,5 Diagnosis of mucormycosis relies on low-sensitivity and time-consuming detection processes, including microscopy, fungal culture, and histopathology. 6 Delayed diagnosis can result in missed optimal treatment time for patients with mucormycosis, leading to an increased mortality rate. However, the clinical symptoms and radiographic manifestations of pulmonary mucormycosis are non-specific, making it susceptible to misdiagnosis as invasive aspergillosis, posing a challenge for etiological diagnosis. 7 In this case, metagenomic next-generation sequencing (mNGS) detection technology was employed to aid in the clinical diagnosis of pulmonary mucormycosis, leading to an adjustment in the treatment plan based on the mNGS test report and resulting in a favorable therapeutic outcome. A 34-year-old man was admitted to our hospital on February 5, 2023, due to a two-day cough and hemoptysis. The patient had a four-year history of epilepsy, with no seizures for the past two years, and was not under drug control. Throughout the illness, the patient's spirit, appetite, and body temperature were normal. The diagnostic and treatment timeline is displayed in Figure 1A. Upon admission, chest CT revealed high-density shadows with blurred margins in the anterior segment of the upper lobe of the right lung. The blood routine test showed a decreased neutrophil ratio, with no abnormalities in other indicators. The inflammatory indicators of WBC count, NE count, and highly-sensitive CRP (Hs-CRP) index of the patient after admission are shown in Figure 1B. The biochemical test results showed that the ALB, ALT, and AST levels decreased significantly, while glucose levels were significantly elevated (Table 1). The changes in these indicators suggested that the patient might have diabetes. On February 6, according to the results of glycated hemoglobin examination and routine urinalysis, the patient was initially diagnosed with diabetes, and the shadow of the lung needed further examination. Table 1 Results of blood routine and biochemical tests Figure 1 Timeline of diagnosis and treatment in this case. ( A ) The timeline recorded essential events of the patient during hospitalization. The Orange dot indicates mNGS test, and the green dots indicate other test items and key events. ( B ) Trends in inflammatory indicators. On February 7, a bronchoscopy revealed a caseous necrotic material in the right lung's upper lobe. On February -Abstract Truncated-
pharmacology & pharmacy,infectious diseases